Skip to content
Sexuality – Lifestyle
Author:
Infex Therapeutics
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
May 21, 2026
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
May 12, 2026